**Patient with tissue expander in place and evidence of breast cellulitis**

**Acute SSTI not involving the expander**
Suggested by:
- Acute onset
- Trace/no fluid around the expander
- Negative fluid culture (if done)
- First episode of infection

**Outpatient therapy**
- Okay if no systemic symptoms or significant lab abnormalities
- Empiric PO regimen:
  - TMP-SMX
  - If TMP-SMX allergy: doxy/cipro
  - No rifampin
  - Duration of therapy = 2 wks

**Inpatient therapy**
- Empiric IV regimen: vanc/cefepime
- Discharge with orals
  - Step-down to doxy/cipro
  - If previously on doxy then consider linezolid (or clinda if on SSRI or insurance issues)
  - No rifampin
  - Duration = to complete 2 wks

**Initial work-up:**
- Evaluate for fluid (clinically or get US)
- If fluid is present, aspirate via expander port or via IR and send for bacterial cx
- Consider uPCR and AFB cultures for indolent infection and/or culture-negative cases (especially if recurrent)

**Tissue expander infection**
Suggested by:
- Large amount of fluid around expander
- Positive fluid culture
- Recurrent infection
- Late onset (>30d from last surgery or expansion)
- No obvious portal of entry (no skin break)

**TISSUE EXPANDER REMOVAL**
**Indications for removal**
- Not improving on IV antibiotics
- Multiple recurrences or recurrence on Abx (if removal is not feasible, chronic suppression may be considered)
- S. aureus, Pseudomonas, Candida, or NTM

**Removal without replacement** (preferred if above organisms or gross purulence/thick biofilm intra-op)
- Duration = 2-4 weeks depending on intra-op findings and degree of source control
- No rifampin

**Removal with single stage replacement** (preferred over salvage if any cultures positive)
- Duration = 4 weeks
- Rifampin if Staph isolated (but not if culture-neg)

**Antibiotic Regimen**
- IV while hospitalized: vanc/cefepime
- Orals at discharge (unless particularly severe infection, lack of good source control; this is rare)
  - Treat as per organism if positive cultures
  - If culture negative: doxy/cipro
- Rifampin as indicated above

**TISSUE EXPANDER SALVAGE**
- Use in particular if XRT in last 6 mo b/c of poor healing
- Antibiotic regimens as above
- Rifampin if Staph isolated (but not if culture-neg)
- Duration = 6 weeks
**Additional Notes**

**Notes on antibiotic dosing**

- Cefepime and ciprofloxacin: use non-Pseudomonal dosing unless Pseudomonas is isolated
  - Cefepime: for normal renal function, non-Pseudomonal dosing is 2gm IV q12 and Pseudomonal dosing is 2gm IV q8h
  - Ciprofloxacin: for normal renal function, non-Pseudomonal dosing is 500mg PO bid and Pseudomonal dosing is 750mg PO bid
- For dosing questions, please contact ID or ID pharmacy
- TMP-SMX dosing (for normal renal function; if CrCl<50 please call ID or ID Pharmacy for assistance):
  - 40-59kg: 1 DS tab PO BID
  - 60-70kg: 1 DS tab PO TID
  - >80kg: 2 DS tab PO BID
- Note, TMP-SMX = Trimethoprim-Sulfamethoxazole. The DS tab is the ‘double strength’ tablet which contains 160mg of the TMP (trimethoprim) component.

**Peri-operative Antibiotics for Tissue Expander Surgery**

Peri-operative decolonization (ortho protocol):
- 3 consecutives days of CHG soap pre-op
- CHG body wipes during inpatient stay
- Betadine nasal swabs bid starting in pre-op holding area and continuing x 5 days or hospital discharge, whichever comes first
- Peri-operative antibiotic choice: cefazolin
- Peri-operative antibiotic duration: in clean and clean-contaminated surgeries, discontinue antibiotics after the surgical incision is closed unless the patient has a documented or suspected infection (even if drains in place)
- Complete UCSF surgical prophylaxis guidelines: [https://idmp.ucsf.edu/content/surgical-prophylaxis-guidelines](https://idmp.ucsf.edu/content/surgical-prophylaxis-guidelines)

**Internal Review of Tissue Expander Infection Positive Results (Inpatients, 9/2019-11/2020)**

- 74% Gram positives (22% MRSE, 11% MSSE, 7% Staph epi, 4% MRSA, 15% MSSA, 7% P acnes)
- 26% GNRs (11% Serratia, 7% Pseudomonas)

**References**

Banuelos et al, Ann Plast Surg 202; 85:194